TABLE 1.
The detailed results of successfully established zPDX of gastric cancer patients.
| Patient no. | Tumor recurrence1 |
Postoperative adjuvant chemotherapy2 |
Follow-up (m) | zPDX3 | |||
| Status | Time (m) | Evidence | Regimen | Regimen changing | Chemosensitivity results | ||
| #1 | NO | NO | NO | 20 | All resistance | ||
| #6 | NO | Capecitabine | NO | 18 | CDDP***, 5-FU**, Dox*, DXTr | ||
| #9 | NO | CAPEOX | NO | 17 | 5-FU*, CDDP*, DXT*, Doxr | ||
| #11 | NO | FOLFORI | NO | 15 | DXT***, 5-FU*, CDDPr, Doxr | ||
| #15 | NO | CAPEOX | NO | 15 | 5-FU***, DXT***, CDDPr, Doxr | ||
| #16 | NO | Capecitabine | NO | 14 | 5-FU***, DXT***, CDDPr, Doxr | ||
| #20 | YES | 6 | AFP↑ (16.40) | TP | Capecitabine | 14 | 5-FU*, DXTr, CDDPr, Doxr |
| #23 | NO | Capecitabine | NO | 14 | All resistance | ||
| #25 | NO | FOLFORI | NO | 14 | 5-FU*, DXTr, CDDPr, Doxr | ||
| #27 | YES | 6 | CEA↑ (5.40) | FOLFORI | FOLFOX | 14 | CDDP***, 5-FU***, DXT***, Dox*** |
| #29 | NO | Capecitabine | NO | 13 | 5-FU***, CDDP***, Dox***, DTX*** | ||
| #32 | NO | FLOT | NO | 13 | DXT***, 5-FU***, CDDPr, Doxr | ||
| #34 | NO | Capecitabine | NO | 12 | 5-FU*, Doxr, CDDPr, DXTr | ||
| #35 | YES | 12 | CEA↑ (6.25) | FLOT | TP | 12 | 5-FU*, DXTr, Doxr, CDDPr |
| #36 | NO | FOLFORI | NO | 12 | DXT*, CDDP*, Doxr, 5-FUr | ||
| #38 | NO | DCF | NO | 12 | 5-FU*, DXTr, Doxr, CDDPr | ||
| #39 | NO | FLOT | NO | 11 | 5-FU*, DTX*, CDDP*, Doxr | ||
| #41 | NO | FOLFORI | NO | 11 | 5-FU*, DXT*, CDDPr, Doxr | ||
| #43 | YES | 7 | CT (lymph nodes) | FLOT | NO | 11 | All resistance |
| #45 | NO | FOLFOX | NO | 11 | CDDP*, DXT*, Dox*, 5-FUr | ||
| #47 | YES | 7 | CEA↑ (10.64) Die at 9 m. | Capecitabine | NO | 10 | All resistance |
| #48 | NO | FOLFOX | NO | 10 | 5-FU*, DXTr, Doxr, CDDPr | ||
| #50 | NO | FLOT | NO | 10 | 5-FU**, Doxr, CDDPr, DXTr | ||
| #52 | NO | TP | NO | 10 | DXT*, CDDPr, 5-FUr, Doxr | ||
| #53 | NO | Capecitabine | NO | 8 | 5-FU*, CDDP*, Doxr, DXTr | ||
| #54 | NO | Capecitabine | NO | 8 | CDDP***, DXT***, 5-FU***, Doxr | ||
| #55 | YES | 5 | CT (lymph nodes) | FOLFOX | FLOT | 8 | All resistance |
| #56 | NO | Capecitabine | NO | 8 | DXT**, 5-FU**, CDDPr, Doxr | ||
1Tumor recurrence was monitored continuously by measuring serum tumor markers or image study. “YES” means recurrence, and we showed the recurrence time (months after surgery) and the evidences. 2Most patients have undergone postoperative adjuvant chemotherapy, and some patients’ regimens were changed due to recurrence or other reasons. (“NO” means the patient did not receive adjuvant chemotherapy or the patient’s regimen did not change during therapy.) 3In this study, the zPDX models were established in 28 cases successfully, and the chemosensitivity of 5-FU, CDDP, DXT, and Dox was obtained (“*–***” means the treatment inhibited cell proliferation significantly, *P < 0.05, **P < 0.01, and ***P < 0.001. “r” means resistance to the drug. “All resistance” means resistance to these four drugs).